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Objectives The study aimed to evaluate inclacumab for the reduction of myocardial damage during a percutaneous coro-
nary intervention (PCI) in patients with non–ST-segment elevation myocardial infarction.
Background P-selectin is an adhesion molecule involved in interactions between endothelial cells, platelets, and leukocytes.
Inclacumab is a recombinant monoclonal antibody against P-selectin, with potential anti-inflammatory, anti-
thrombotic, and antiatherogenic properties.
Methods Patients (N  544) with non–ST-segment elevation myocardial infarction scheduled for coronary angiogra-
phy and possible ad hoc PCI were randomized to receive 1 pre-procedural infusion of inclacumab 5 or 20
mg/kg or placebo. The primary endpoint, evaluated in patients who underwent PCI, received study medica-
tion, and had available efficacy data (n  322), was the change in troponin I from baseline at 16 and 24 h
after PCI.
Results There was no effect of inclacumab 5 mg/kg. Placebo-adjusted geometric mean percent changes in troponin I
with inclacumab 20 mg/kg were 24.4% at 24 h (p  0.05) and 22.4% at 16 h (p  0.07). Peak troponin I
was reduced by 23.8% (p  0.05) and area under the curve over 24 h by 33.9% (p  0.08). Creatine kinase-
myocardial band yielded similar results, with changes of 17.4% at 24 h (p  0.06) and 16.3% at 16 h
(p  0.09). The incidence of creatine kinase-myocardial band increases 3 times the upper limit of normal
within 24 h was 18.3% and 8.9% in the placebo and inclacumab 20-mg/kg groups, respectively (p  0.05).
Placebo-adjusted changes in soluble P-selectin level were 9.5% (p  0.25) and 22.0% (p  0.01) with in-
clacumab 5 and 20 mg/kg. There was no significant difference in adverse events between groups.
Conclusions Inclacumab appears to reduce myocardial damage after PCI in patients with non–ST-segment elevation myocar-
dial infarction. (A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction [Non-STEMI] Un-
dergoing Percutaneous Coronary Intervention; NCT01327183) (J Am Coll Cardiol 2013;61:2048–55) © 2013
by the American College of Cardiology Foundation
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This is an open access article under the CC BY-NC-NDPercutaneous coronary intervention (PCI) is a widely used
revascularization procedure for patients with stable and
unstable coronary artery disease, but varying degrees of
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May 21, 2013:2048–55 Results of the SELECT-ACS Trialuneventful PCI (1–3). Although the pathophysiology of
post-PCI myocardial damage is multifactorial, inflamma-
tion and platelet activation appear to play pivotal roles
(4–7). P-selectin, a cell adhesion molecule expressed on
activated endothelial cells and platelets, plays a critical role
in leukocyte tethering and rolling on the vessel wall and
subsequent diapedesis through interactions with P-selectin
glycoprotein ligand 1 (8). It also promotes platelet rolling
and adhesion to the activated vessel wall. When expressed
on the cell surface, P-selectin therefore affects both the
inflammatory and thrombotic cascades, induces formation
of procoagulant microparticles, and mediates microparticle
and leukocyte recruitment to thrombi, which collectively
promotes both leukocyte recruitment to activated endothe-
lium and thrombus growth and stabilization (9). Studies in
mice, rats, and pigs have suggested that inhibition of
P-selectin with either an anti–P-selectin monoclonal anti-
body or P-selectin glycoprotein ligand 1–immunoglobulin
complex can significantly decrease neutrophil and platelet
adhesion, macrophage accumulation, and neointimal for-
mation after arterial injury (10–13). Inclacumab is a highly
specific human recombinant monoclonal antibody against
P-selectin, which has been shown to reduce CD11b expres-
sion (known to increase after PCI [14]) on neutrophils in a
concentration-dependent fashion (data on file, F.
Hoffmann-La Roche). The SELECT-ACS (Effects of the
P-Selectin Antagonist Inclacumab on Myocardial Damage
After Percutaneous Coronary Intervention for Non-ST-
Elevation Myocardial Infarction) clinical trial was designed
to determine the efficacy of inclacumab in reducing myo-
cardial damage during PCI in patients with non–ST-
segment elevation myocardial infarction (NSTEMI). We
hypothesized that inclacumab would reduce myocardial
damage through the effects of P-selectin inhibition on both
the inflammatory and thrombotic cascades.
Methods
Study design and procedures. This prospective, interna-
tional, multicenter, randomized, double-blind, placebo-
controlled trial evaluated the efficacy and safety of in-
clacumab (RO4905417, F. Hoffmann-La Roche) in
patients with NSTEMI scheduled for coronary angiography
and PCI. The study was coordinated by the Montreal Heart
Institute Coordinating Center. Patients reviewed and
signed an informed consent form approved by the institu-
tional review boards of the study sites before any study-
related procedures. Patient screening was performed up to 3
days before PCI, followed by treatment involving a single
investigator for a past Roche-sponsored trial. Dr. Tanguay is a consultant to Roche.
Dr. Wright is a research consultant to Roche/Genentech, 3M, and Sanofi Regeneron,
and is a consultant to Gilead. Dr. Ibrahim is a proctor and consultant for St. Jude and
Gore. All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose.Manuscript received February 22, 2013; revised manuscript received February 28,
2013, accepted March 2, 2013.infusion of inclacumab (5 or 20
mg/kg) or placebo before PCI.
Patients were monitored for 24 h for
efficacy and 120 days for safety eval-
uations (Fig. 1). Troponin I (TnI)
and creatine kinase-myocardial
band (CK-MB) levels were mea-
sured in a central laboratory.
The study drug was adminis-
tered between 1 and 24 h before
PCI over a 1-h infusion period.
Patients were randomized in a
1:1:1 ratio to 3 treatment arms:
inclacumab 5 mg/kg, inclacumab
20 mg/kg, or placebo. A strati-
fied randomization was used to account for the presence or
absence of known diabetes to ensure equal distribution
within the randomized groups. A randomization schedule
was generated using SAS statistical software version 9.3
(SAS Institute, Cary, North Carolina). Patients received
concomitant evidence-based therapies as currently recom-
mended by the American College of Cardiology/American
Heart Association guidelines. This included the adminis-
tration of aspirin, a P2Y12 inhibitor, lipid-lowering medi-
cations (preferably a statin), and a renin-angiotensin system
inhibitor as deemed necessary by the investigator. Patients
were assessed at baseline and at 8, 16, and 24 h post-PCI or
at the time of discharge if patients were discharged before
the last time point. All patients returned 30 and 120 days
post-infusion for follow-up safety visits that included the
assessment of adverse events, routine clinical laboratory
tests, physical examination, and electrocardiograms. A sub-
set of the enrolled patients (n  177) willing to participate
in an optional substudy had additional blood samples
collected at baseline and at 8 h post-PCI for the measure-
ment of plasma-soluble P-selectin levels using a specific
enzyme-linked immunosorbent assay (R&D Systems Inc.,
Minneapolis, Minnesota).
Study population. A total of 544 patients at 66 centers
located in Canada, the United States, Poland, and the
Netherlands were enrolled in this study. Patients were
included in the study if they were between 18 and 85 years
old, were diagnosed with NSTEMI as defined by the
American College of Cardiology/American Heart Associa-
tion guidelines, and scheduled for coronary angiography and
possible ad hoc PCI. Reasons for exclusion were PCI within
the past 72 h; recent thrombolytic therapy; recent cerebro-
vascular disease or stroke; bleeding disorders; significant
blood dyscrasia; severe uncontrolled hypertension; previous
coronary artery bypass graft surgery; active or recent chronic
bacterial, parasitic, or viral infection; uncontrolled diabetes
mellitus; intercurrent infection; severe renal failure; hepatic
failure; severe active inflammatory or immune-mediated
disease; pregnancy or planned pregnancy; or any other
condition or disease that would render the patient unsuit-
Abbreviations
and Acronyms
ANCOVA  analysis of
covariance
AUC  area under the
curve
CK-MB  creatine kinase-
myocardial band
NSTEMI  non–ST-segment
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infusion but did not undergo the planned PCI procedure
were not evaluated for efficacy, but were followed for safety
assessments.
Study endpoints. Efficacy analyses were conducted in pa-
tients who received the study drug (or placebo) infusion,
underwent PCI, and had TnI levels available at both
baseline and follow-up. The primary efficacy endpoint was
the change from baseline in TnI evaluated at both 16 and
24 h (or time of discharge, whichever was earlier) post-PCI.
The secondary endpoints of this study were the peak TnI
post-PCI, the area under the curve (AUC) for TnI over the
24-h period after PCI, the change from baseline in TnI at
8 h post-PCI, and the changes from baseline in CK-MB at
8, 16, and 24 h post-PCI.
Safety analyses were performed on all patients who received
study medication regardless of whether they proceeded to PCI.
Safety was assessed through reporting of adverse events, clinical
laboratory test results, and physical examination including vital
signs and 12-lead electrocardiograms.
Statistical analysis. Baseline, efficacy, and safety data are
reported using descriptive statistics. Mean, SD, median, and
minimum and maximum are presented for continuous vari-
ables; count and frequency are presented for categorical vari-
ables. The primary endpoint was analyzed using a repeated-
measures analysis of covariance (ANCOVA) adjusting for
baseline value of TnI and for the stratification factor (presence
or absence of diabetes before acute coronary syndrome). Each
Figure 1 Overview of Study Design and Patient Disposition
A total of 544 patients were enrolled in the study. A total of 322 patients received
ponin I levels available at both baseline and follow up (efficacy population). Safety
whether or not they proceeded to PCI (n  530).active treatment group was compared with placebo using dappropriate contrasts. The secondary endpoints expressed as
changes from baseline were analyzed using a similar repeated-
measures ANCOVA model. Comparisons of peak TnI be-
tween active treatment and placebo groups were conducted
using an ANCOVA model adjusting for baseline TnI and
diabetes. The 24-h AUC for TnI was analyzed using an
analysis of variance model adjusting for diabetes. Change from
baseline to 8 h post-PCI in soluble P-selectin levels, available
in a subgroup of patients, was analyzed using an ANCOVA
model adjusting for baseline level and diabetes.
A log transformation was applied to these efficacy
endpoints because of skewed distribution. Differences
between the active treatment and placebo groups were
therefore described through placebo-adjusted geometric
mean percent change. The geometric mean is obtained by
the antilog of log-transformed data. Placebo-adjusted
geometric mean percent change at 24 h is equal to
[(geometric mean for change at 24 h with inclacumab 
geometric mean for change at 24 h with placebo)/
geometric mean for change at 24 h with placebo]  100.
All testing was 2 sided and conducted at the 0.05
ignificance level. No adjustments were made for multiple
omparisons. Statistical analyses were performed using SAS
tatistical software version 9.3 (SAS Institute).
ample size estimation. The sample size was based on the
omparison of 2 means of TnI with an alpha level of 0.05.
he calculation of sample size used previously published
ata on troponin after PCI (15) based on log-transformed
medication, underwent percutaneous coronary intervention (PCI) and had tron-
ses were performed on all patients who received study medication regardless ofstudy
analyata that showed that the average SD of log TnI the first
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May 21, 2013:2048–55 Results of the SELECT-ACS Trial24 h after PCI was 1.5 and that the geometric mean in the
placebo group was 1.0 ng/ml. To detect a 40% reduction
in TnI, the study required 137 patients per group (411
total). Because it was estimated that 20% of the randomized
patients might not be eligible to undergo PCI and to ensure
that sufficient numbers of patients would be randomized,
treated, and undergo PCI, 172 patients per group (516
total) were targeted for enrollment.
Results
A total of 322 patients received study medication, under-
went PCI, and had TnI levels available at both baseline and
follow-up (see Fig. 1 for patient disposition). The popula-
ion was primarily white (96.0%) and male (78.9%), with a
edian age of 61.1 years. Most patients received drug-
luting (58.1%) or bare metal (36.7%) stents during PCI.
here were no differences in baseline characteristics among
he 3 treatment groups (n  115 for placebo, n  95 for
nclacumab 5 mg/kg, n  112 for inclacumab 20 mg/kg)
Table 1).
fficacy of inclacumab 5 mg/kg. Treatment with in-
lacumab 5 mg/kg did not demonstrate any effect on
Patient Demographics and Baseline CharacterisTable 1 Patient Demographics and Baseline
Placebo
(n  115)
Age, yrs 60.9 (54.4–66.6)
Sex
Male 79.1
Female 20.9
Race
White 95.7
Asian 0.0
Black or African American 3.5
Other 0.9
Diabetes, % 20.9
Duration of PCI, min 20.0 (14.0–40.0)
No. of vessels treated/patient 1.0 (1.0–1.0)
Reference vessel diameter, mm* 3.0 (2.5–3.5)
Total stent length, mm n  108
22.0 (15.0–30.0)
Stent type, no. of stents n  147
Drug-eluting 59.2
Bare-metal 35.4
None 5.4
P2Y12 antagonist before PCI 79.8
Glycoprotein IIb/IIIa antagonist 17.4
Aspirin 96.6
Statins 96.0
Angiotensin-converting enzyme
inhibitors
75.4
Angiotensin II receptor
antagonists
14.3
Beta-blockers 90.3
Values are median (interquartile range) or %. *Reference vessel diam
PCI  percutaneous coronary intervention.educing periprocedural myocardial damage. There was no 8tatistically significant effect on the placebo-adjusted geo-
etric mean percent changes from baseline in TnI at 16 h
ost-PCI (3.4%, p  0.81), in TnI at 24 h post-PCI
1.4%, p  0.93), in peak TnI (1.5%, p  0.92), in the
UC over 24 h for TnI (27.2%, p  0.19), and in
K-MB at 16 h (7.0%, p  0.50) and at 24 h (4.7%,
 0.64) post-PCI after pre-treatment with inclacumab 5
g/kg (Tables 2 and 3).
fficacy of inclacumab 20 mg/kg. Treatment with in-
lacumab 20 mg/kg resulted in placebo-adjusted geometric
ean percent changes in TnI of 24.4% at 24 h (p  0.05)
Table 2, Fig. 2) and 22.4% at 16 h (p  0.07). The
ddition of the patients who had cardiac biomarker measure-
ents but did not receive the infusion to the analysis of the
rimary endpoint yielded identical results. Peak TnI and the
UC for TnI were also lower compared with placebo
23.8%, p 0.05 and33.9%, p 0.08, respectively (Table
). Likewise, inclacumab was associated with placebo-adjusted
eometric mean percent changes in CK-MB of 17.4% at
4 h (p 0.06) and16.3% at 16 h (p 0.09) (Fig. 3). The
ncidence of increases in CK-MB greater than 3 times the
pper limit of normal was 18.3% in the placebo group and
racteristics
clacumab
5 mg/kg
(n  95)
Inclacumab
20 mg/kg
(n  112)
All
(N  322)
(55.4–70.6) 59.8 (53.4–68.7) 61.1 (54.5–69.0)
77.9 79.5 78.9
22.1 20.5 21.1
95.8 96.4 96.0
0.0 0.9 0.3
4.2 2.7 3.4
0.0 0.0 0.3
24.2 23.2 22.7
(13.0–36.0) 25.5 (16.0–40.0) 23.0 (15.0–40.0)
0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
0 (2.5–3.5) 3.0 (2.5–3.4) 3.0 (2.5–3.5)
n  88 n  109 n  305
(16.0–29.0) 22.0 (16.0–30.0) 20.0 (15.0–30.0)
n  116 n  138 n  401
58.6 56.5 58.1
35.3 39.1 36.7
6.0 4.3 5.2
78.5 81.8 80.1
16.8 19.6 18.0
91.1 92.0 93.2
94.4 94.9 95.1
71.5 79.0 75.3
19.0 9.7 14.3
90.5 92.0 90.9
s evaluated visually in the catheterization laboratory.ticsCha
In
63.1
22.0
1.
3.
20.0.9% with inclacumab 20 mg/kg (p  0.05).
corona
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Results of the SELECT-ACS Trial May 21, 2013:2048–55The effect of inclacumab 20 mg/kg was similar in patients
with or without diabetes. Placebo-adjusted changes in TnI
at 16 and 24 h were 29.0% (p  0.03) and 36.1% (p 
0.01), respectively, in patients not treated with glycoprotein
2b3a inhibitors (n  264) and 0.8% (p  0.98) and
12.3%, respectively (p  0.71) in the others (n  58).
Corresponding changes in CK-MB were 20.3% (p 
0.05) and 23.1% (p  0.02) without background 2b3a
inhibition and6.9% (p 0.78) and17.8% (p 0.42) in
those also treated with a IIb/IIIa inhibitor.
Safety. Overall, 22.6% of the patients who received study
medication (N  530) reported at least 1 serious adverse
event, and the percentages of serious adverse events were
18.3%, 24.0%, and 25.6% in the placebo, inclacumab 5
mg/kg, and 20 mg/kg groups, respectively (Table 4). Most
adverse events were of mild or moderate intensity and
resolved without sequelae. Overall, the pattern and nature of
adverse events were similar in the placebo and the active
treatment groups. No clinically significant or dose-related
abnormalities were found on electrocardiography or vital
signs, and no dose-related abnormalities were reported in
laboratory parameters. There were no apparent effects on
infection rates or bleeding. The number of major adverse
cardiovascular events, including deaths, nonfatal myocardial
infarctions, strokes, and cardiac arrests (reported events
Primary Efficacy Parameters: Change in TroponiTable 2 Primary Efficacy Parameters: Chang
Troponin I
Baseline GM (interquartile range) 1
16 h post-PCI GM
Adjusted GM percent change from baseline to 16 h
Placebo-adjusted GM percent change at 16 h
95% CI
p value
24 h post-PCI GM
Adjusted GM percent change from baseline to 24 h
Placebo-adjusted GM percent change at 24 h
95% CI
p value
Placebo-adjusted GM percent change at 24 h
Diabetic patients
95% CI
p value
Nondiabetic patients
95% CI
p value
Periprocedural IIb/IIIa inhibition
95% CI
p value
No periprocedural IIb/IIIa inhibition
95% CI
p value
CI  confidence interval; GM  geometric mean; PCI  percutaneouswere independently adjudicated), was small. There were 0,4, and 2 deaths in the placebo, inclacumab 5 mg/kg, and
inclacumab 20 mg/kg groups, respectively.
Plasma soluble P-selectin levels. In the subset of patients
participating in the optional substudy (n  177), only the
higher dose of inclacumab demonstrated a significant effect
on soluble P-selectin levels at 8 h. Placebo-adjusted geo-
metric mean percent changes were 9.5% with inclacumab
5 mg/kg (n  53, p  0.25) and 22.0% with inclacumab
20 mg/kg (n  63, p  0.01) (Fig. 4).
Discussion
This randomized, placebo-controlled international multi-
center phase 2 study tested the specific P-selectin monoclo-
nal antibody inclacumab given as a single injection before
coronary angiography and ad hoc PCI in patients with
NSTEMI. Inclacumab at a dose of 20 mg/kg was found to
consistently reduce TnI and CK-MB levels post-PCI,
although the results were of borderline statistical signifi-
cance. Similarly, the incidence of CK-MB increases 3
times the upper limit of normal was reduced with in-
clacumab 20 mg/kg compared with placebo. Inclacumab at
the same dose was also found to reduce significantly the
plasma level of soluble P-selectin. These are encouraging
results supporting beneficial biological effects of this
P-selectin antagonist, which need to be confirmed in a
16 and 24 hTroponin I at 16 and 24 h
cebo
115)
Inclacumab
5 mg/kg
(n  95)
Inclacumab
20 mg/kg
(n  112)
24–4.69) 0.71 (0.17–3.44) 0.82 (0.19–3.73)
 114) 1.30 (n 94) 1.09 (n 108)
7.4 71.3 37.6
3.4 22.4
27.2 to 28.2 40.8 to 1.7
0.81 0.07
 104) 1.21 (n 92) 0.99 (n 101)
7.7 55.5 19.1
1.4 24.4
(26.7 to 32.7) (43.1 to 0.4)
0.93 0.05
29.0 (n 23) 33.2 (n 24)
63.5 to 38.0 65.4 to 29.0
0.31 0.23
4.2 (n 69) 31.6 (n 77)
32.5 to 36.0 51.3 to3.9
0.81 0.03
43.4% (n 15) 12.3% (n 20)
32.1 to 202.5 56.2 to 75.5
0.34 0.71
18.5% (n 77) 36.1% (n 81)
41.9 to 14.1 54.1 to11.0
0.23 0.01
ry intervention.n I ate in
Pla
(n 
.03 (0.
1.74 (n
7
—
1.76 (n
5
—larger clinical trial.
d 2.
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May 21, 2013:2048–55 Results of the SELECT-ACS TrialMyocardial damage after PCI. PCI can induce an inflam-
matory response (16,17), even during apparently uneventful
procedures. Damage to the vascular wall during intervention
leads to activation of endothelial cells, leukocytes, and
platelets (6,7,16,17). Statins have been shown in small
clinical studies to reduce TnI release after PCI, both in
patients with stable coronary disease and after ACS (18–
21), and this benefit has been attributed to their anti-
inflammatory activity. Similarly, an anti-inflammatory
viral serpin has been shown to reduce the release of
myocardial damage markers after PCI in a small clinical
trial (15). P-selectin antagonism has been shown in
multiple animal studies to decrease the adhesion of
neutrophils and platelets and the accumulation of mac-
rophages after arterial injury (10 –13). More specifically,
inclacumab reduces neutrophil activation (CD11b ex-
pression) and platelet-leukocyte aggregates by as much as
95% (data on file, F. Hoffmann-La Roche). The latter
effect on platelet-leukocyte aggregates may contribute to
a reduction in the risk of microembolization during PCI
and could account at least in part for the reduction in
levels of myocardial damage markers seen in patients
Secondary Efficacy Parameters: Changes in Troponin I and CK-MBTable 3 Secondary Efficacy Parameters: Changes in Troponin I
CK-MB
Baseline geometric mean (IQR)
8 h post-PCI GM
Adjusted GM percent change from baseline to 8 h
Placebo-adjusted GM percent change at 8 h
95% CI
p value
16 h post-PCI GM
Adjusted GM percent change from baseline to 16 h
Placebo-adjusted GM percent change at 16 h
95% CI
p value
24 h post-PCI GM
Adjusted GM percent change from baseline to 24 h
Placebo-adjusted GM percent change at 24 h
95% CI
p value
Peak TnI geometric mean
Placebo-adjusted GM percent change in peak TnI
95% CI
p value
TnI area under the curve GM
Placebo-adjusted GM percent change in TnI area under the curve (over 24 h)
95% CI
p value
Adjusted GM percent change in TnI from baseline to 8 h
Placebo-adjusted GM percent change in TnI at 8 h
95% CI
p value
CK-MB  creatine kinase-myocardial band; TnI  troponin I; other abbreviations as in Tables 1 antreated with inclacumab 20 mg/kg.Safety of inclacumab. Inclacumab appeared to have been
tolerated well in the SELECT-ACS trial, although the
percentage of patients with serious adverse events was
Figure 2 Percent Change in Troponin I Over Time
The black line represents placebo, the orange line represents inclacumab
5 mg/kg, and the blue line represents inclacumab 20 mg/kg. PCI  percutane-
ous coronary intervention.
CK-MB
Placebo
(n  115)
Inclacumab 5 mg/kg
(n  95)
Inclacumab 20 mg/kg
(n  112)
.46 (3.60–23.70) 7.54 (2.70–15.50) 7.97 (3.10–17.85)
9.29 (n 113) 7.28 (n 93) 7.25 (n 110)
3.6 5.1 8.6
— 8.5 11.9
23.6 to 9.7 25.8 to 4.8
0.34 0.15
9.57 (n 114) 7.93 (n 94) 7.29 (n 108)
6.5 1.0 10.9
— 7.0 16.3
— 25.0 to 15.2 31.9 to 2.7
0.50 0.09
8.07 (n 104) 6.57 (n 92) 5.83 (n 102)
15.0 19.0 29.8
— 4.7 17.4
— 22.3 to 16.9 32.1 to 0.4
0.64 0.06
2.09 1.56 1.34
— 1.5 23.8
26.3 to 31.6 42.2 to 0.5
0.92 0.05
40.37 28.87 26.35
— 27.2 33.9
54.8 to 17.2 58.1 to 4.3
0.19 0.08
58.9 51.8 27.4
— 4.5 19.8
— 25.9 to 23.2 37.1 to 2.3
0.72 0.08and
9
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Results of the SELECT-ACS Trial May 21, 2013:2048–55numerically higher in those treated with inclacumab. De-
spite the role of the P-selectin pathway in the interactions
between endothelium, leukocytes, and platelets, inclacumab
was not associated with infections and bleeding. The num-
ber of major adverse cardiovascular events was small; 4
deaths occurred in the inclacumab 5 mg/kg group, 2 in the
inclacumab 20 mg/kg group, and none in the placebo group.
There was also a numerical excess of myocardial infarctions
(4, 7, and 2 myocardial infarctions, respectively) reported as
cardiovascular events; the significance of this in unclear and
could have been related to the way in which periprocedural
myocardial infarctions were reported by some investigators
or to the play of chance. Indeed, the incidence of CK-MB
increases3 times the upper limit of normal was reduced in
Figure 3 Percent Change in CK-MB Over Time
The black line represents placebo, the orange line represents inclacumab
5 mg/kg, and the blue line represents inclacumab 20 mg/kg. CK-MB  crea-
tine kinase-myocardial band; PCI  percutaneous coronary intervention.
Safety SummaryTable 4 Safety Summary
Plac
(n 
No. of treatment emergent SAEs 4
Patients with at least 1 treatment emergent SAE 32 (1
Patients with SAE leading to study drug interruption or withdrawal 0 (0
No. treatment emergent AEs 33
Patients with treatment emergent infection 21 (1
Patients with AE occurring within 24 h of infusion start 57 (3
Patients with bleeding at up to 30 days 6 (3
Patients with bleeding at up to 120 days 9 (5
Occurrence of major bleed at 120 days 3 (1
All-cause death
Nonfatal MI*
Stroke
Hospitalized for ACS 24 h
Resuscitated cardiac arrest
Patients with at least 1 revascularization procedure 2
Patients with hospitalization for CHF
Renal failureValues are n or n (%). *Some periprocedural myocardial infarctions were reported as nonfatal MIs accord
ACS  acute coronary syndrome; AE  adverse event; CHF  congestive heart failure; MI  myocardithe inclacumab 20 mg/kg group compared with the placebo
group (8.9% vs. 18.3%).
Study limitations. Efficacy analyses were conducted in patients
who received the infusion, underwent PCI, and had TnI levels
available at baseline and follow-up; this was not an intention-to-
treat analysis involving all patients randomized in the study. The
amount of myocardium at risk was not specifically measured in
this study. Also, we did not collect the time between hospital
admission and PCI. The SELECT-ACS trial was not powered
for the evaluation of clinical endpoints. Although TnI and
CK-MB are reliable biomarkers of myocardial damage, the
clinical significance of post-PCI elevations remains open to
Figure 4 Change in Plasma-Soluble P-Selectin at
8 h Post-PCI
The black line represents placebo, the orange line represents inclacumab
5 mg/kg, and the blue line represents inclacumab 20 mg/kg. PCI  percutane-
ous coronary intervention.
Inclacumab 5 mg/kg
(n  179)
Inclacumab 20 mg/kg
(n  176)
All
(N  530)
63 66 178
43 (24.0) 45 (25.6) 120 (22.6)
1 (0.6) 4 (2.3) 5 (0.9)
396 330 1,058
19 (10.6) 19 (10.8) 59 (11.1)
61 (34.1) 56 (31.8) 174 (32.8)
9 (5.0) 5 (2.8) 20 (3.8)
11 (6.1) 7 (4.0) 27 (5.1)
1 (0.6) 2 (1.1) 6 (1.1)
4 2 6
4 7 13
0 1 1
1 1 4
2 1 4
31 22 73
2 0 2
1 1 3ebo
175)
9
8.3)
.0)
2
2.0)
2.6)
.4)
.1)
.7)
0
2
0
2
1
0
0
1ing to the investigator’s judgment.
al infarction; SAE  serious adverse event.
2055JACC Vol. 61, No. 20, 2013 Tardif et al.
May 21, 2013:2048–55 Results of the SELECT-ACS Trialdebate. Nevertheless, this study supports that P-selectin antago-
nism with inclacumab has favorable biological effects in patients
with NSTEMI undergoing PCI. Although only the higher dose
of inclacumab provided benefits on myocardial damage biomark-
ers, the results were concordant with the reduction in soluble levels
of P-selectin with the 20 mg/kg dose.
Conclusions
The consistency of our data suggests that the P-selectin
antagonist inclacumab reduces myocardial damage after
PCI in patients with NSTEMI. Further clinical investiga-
tion will be required to determine the clinical value (benefit
or harm) of inclacumab in patients presenting with myo-
cardial infarction whether or not they undergo PCI.
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